RT Journal Article SR Electronic T1 Use-dependent relief of inhibition of Nav1.8 channels by A-887826 JF Molecular Pharmacology JO Mol Pharmacol FD American Society for Pharmacology and Experimental Therapeutics SP MOLPHARM-AR-2022-000593 DO 10.1124/molpharm.122.000593 A1 Jo, Sooyeon A1 Zhang, Han-Xiong Bear A1 Bean, Bruce P. YR 2023 UL http://molpharm.aspetjournals.org/content/early/2023/01/10/molpharm.122.000593.abstract AB Abstract Sodium channel inhibitors used as local anesthetics, antiarrhythmics, or anti-epileptics typically have the property of use-dependent inhibition, whereby inhibition is enhanced by repetitive channel activation. For targeting pain, Nav1.8 channels are an attractive target because they are prominent in primary pain-sensing neurons with little or no expression in most other kinds of neurons, and a number of Nav1.8-targeted compounds have been developed. We examined the characteristics of Nav1.8 inhibition by one of the most potent Nav1.8 inhibitors so far described, A-887826, and found that when studied with physiological resting potentials and physiological temperatures, inhibition had strong "reverse use-dependence", whereby inhibition was relieved by repetitive short depolarizations. This effect was much stronger with A-887826 than with A-803467, another Nav1.8 inhibitor. The use-dependent relief from inhibition was seen in both human Nav1.8 channels studied in a cell line and in native Nav1.8 channels in mouse DRG neurons. In native Nav1.8 channels, substantial relief of inhibition occurred during repetitive stimulation by action potential waveforms at 5 Hz, suggesting the phenomenon is likely important under physiological conditions.Significance Statement Nav1.8 sodium channels are expressed in primary pain-sensing neurons and are a prime current target for new drugs for pain. This work shows that one of the most potent Nav1.8 inhibitors, A-887826, has the unusual property that inhibition is relieved by repeated short depolarizations. This “reverse use-dependence” may reduce inhibition during physiological firing and should be selected against in drug development.